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Background/Objective: Mycosis fungoides (MF) comprises the majority of cutaneous T-cell lymphomas
(CTCLs). CTCLs associated with eosinophilia have a poor prognosis. Similar results were shown in white
and black individuals with MF; however, the data on Asians is scant. In the past 10 years, few studies
have provided proﬁles of the characteristics of MF patients in Taiwan. The purpose of this study was to
investigate the demographic, clinicopathologic features, and prognosis of MF patients in Taiwan.
Methods: A retrospective analysis was used to evaluate patients with MF in a referral center in central
Taiwan covering a period of 16 years, from 1997 to 2013. The records of 22 Taiwanese patients with MF
were reviewed for clinical, laboratory, and histopathologic data and evaluated by analysis of variance.
Results: The male to female ratio was approximately 2:1. The average age at diagnosis was 44.8 years.
One pediatric patient presented with hypopigmented MF, and the other 21 patients had typical clinical
manifestations with patches-to-plaques, tumors or erythroderma. Common histopathologic features in
over half of the patients included epidermotropism, atypical lymphocytes, vacuolar interface changes,
and Pautrier's microabscesses. Treatment modalities, including skin-directed and systemic therapies,
primarily depended on the clinical staging. Age 65 years or over (p ¼ 0.004), and Stage IIB disease or
higher (p ¼ 0.026) were signiﬁcant contributors to disease-speciﬁc mortality. There was no signiﬁcant
sex difference in overall survival. Of the 22 patients, 36.3% had blood eosinophilia. Blood eosinophilia was
associated with Stage II disease or higher (p ¼ 0.029) and an increased number of treatment types
(p ¼ 0.018), but not lactate dehydrogenase (LDH).
Conclusion: Age 65 years or over, Stage IIB disease or higher, and blood eosinophilia may be poor
prognostic factors for Taiwanese patients with MF.
Copyright © 2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Primary cutaneous lymphomas represent a rare heterogeneous
entity of T- and B-cell lymphomas, with mycosis fungoides (MF)
comprising the majority of cases. MF accounts for 65% of cutaneous
T-cell lymphoma (CTCL).1 MF is characterized by an indolent clinical
course, a long-term evolution, and typical manifestations in they have no ﬁnancial or non-
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cal Association. Published by Elsevpatch-or-plaque stage, with variable progression to the tumor stage
and erythroderma. Approximately 30% of patients present with
cutaneous tumors or erythroderma at disease onset.2 A conﬁdent
diagnosis of MF needs to take both clinical and histopathologic
ﬁndings into consideration. Characteristic histopathologic and
immunohistochemical features include skin-homing CD4þ lym-
phocytes with epidermotropism or formation of Pautrier's micro-
abscesses, cytologically atypical lymphocytes with hyperchromatic,
cerebriform or vesicular nuclei, a band-like upper dermal inﬁltra-
tion of cytologically atypical cells, and papillary dermal ﬁbrosis.3
Several epidemiologic and laboratory factors were previously
reported to correlate with poor prognosis in patients with MF
includingmale sex,4,5 advanced disease age,4e6 blood eosinophilia,7
elevated serum lactate dehydrogenase (LDH) levels,4,6 and advanced
stages.6 Histopathologic variables that correlated with poorier Taiwan LLC. All rights reserved.
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moderate-to-marked dermal lymphocyte atypia,9 large-sized Pau-
trier's microabscesses with more than 10 atypical lymphocytes per
cluster,9 and diminished proportion of CD7þ and CD8þ cells in the
dermal inﬁltrate.9,10
Although MF is the most common variant of CTCL, it is still a
relatively uncommon malignancy, with estimated annual in-
cidences 3.6e4.5/onemillionperson-years in the United States.11e14
The majority, about 70%, of patients are whites, while blacks, His-
panics, and Asians constitute 14%, 9%, and 7% of MF cases in the
United States, respectively.14 Comparedwith theWestern countries,
MF was rare whereas extranodal natural killer/T-cell lymphoma,
nasal type, was more common in Taiwan.15 Although the prognosis
of MF patients with limited patches and plaques is favorable, there
is a considerable racial difference showing a higher incidence and
poorer outcome among blacks than whites.12,13 It has been sug-
gested that blood eosinophilia may contribute to this racial differ-
ence.16 However, population-based information about Asians,
American Indians, and Hispanics is limited.12,16 Recent epidemio-
logical data about East-Asians with MF has been reported in Hong
Kong,17 Singapore,18 and Japan.6,19 To the best of our knowledge,
few studies conducted in Taiwan in the past 10 years have provided
racial proﬁles. Herein, we retrospectively reviewed the medical
data of MF patients in a referral center in central Taiwan and
investigated the indigenous demographic, clinicopathologic, labo-
ratory, and prognostic characteristics of MF.
Methods
Patients
From September 1997 to August 2013, patients with a diagnosis of
MFwere identiﬁed using the pathology database of the Department
of Pathology of Taichung Veterans General Hospital. Patients were
excluded if theirmedical recordswerenot available for reviewof the
clinical diagnosis and laboratory data. This query generated cases
with both clinically and pathologically conﬁrmed MF.
The demographic proﬁles, clinical presentations, laboratory
data, histopathologic features, stage, types of treatment, and treat-
ment response of all the patients were reviewed. Age at diagnosis
was determined using the date the pathologic diagnosis was made.
Patients were considered as having eosinophilia if their complete
blood cell count was >300 eosinophils/mL of blood, the normal
laboratory standard. Those who had at least one instance of eosin-
ophilia were included in the group. Elevated LDH level was deﬁned
as >240 U/L, the upper limit of normal range in the referral center. A
patient was classiﬁed as having a previous history of eczema if a
medical record noted tentative diagnosis or empirical treatment.
Stage at diagnosis was inferred using the tumor-node-metastasis-
blood (TNMB) staging system forMF. The total number of treatment
types received was determined from clinical notes. Phototherapy
with narrowband UV-B (NB-UVB) and photochemotherapy with
psoralen and UV-A (PUVA) were viewed as different types of
treatment. Other types of treatment included topical corticoste-
roids, retinoids, interferon-a, and pegylated liposomal doxorubicin.
Histopathologic variables included Pautrier's microabscesses,
deﬁned as clusters of three or more atypical lymphocytes in the
epidermis, epidermotropism with tagging of lymphocytes along the
basal layer to diffuse exocytosis of lymphocytes in all layers of the
epidermis, dermal inﬁltrate, atypical lymphocytes with hyper-
chromatic or cerebriform nuclei, with or without increased mitotic
ﬁgures, presence or absence of follicular mucinosis, ﬁbrosis of
papillary dermis, and eosinophils, plasma cells, and histiocytes in the
dermal inﬁltrate. Lymphocyte surface markers including CD3, CD4,
CD8, and CD20 were routinely studied by immunohistochemistry.Approval for this retrospective chart review was obtained from
the Institutional Review Board of Taichung Veterans General Hos-
pital in Taichung, Taiwan.
Statistical analysis
Because of the small sample size, Fisher's exact test and Pearson's
Chi-square test were conducted to analyze the differences in cat-
egorical variables in 2 2 and r c contingency tables, respectively.
The Pearson correlation coefﬁcient was used to measure the
strength of association between two continuous variables. All tests
were two-sided. A p value <0.05 was considered statistically sig-
niﬁcant. All statistical analyses were performed using SPSS version
17 (SPSS Inc., Chicago, IL, USA).
Results
Epidemiology
Of the 23 patients with a pathologic diagnosis of MF over the period
of 16 years, one patient for whom there was no clinical information
was excluded. In our data set, there were 22 Taiwanese patients
with both clinically and pathologically conﬁrmed MF (Table 1). The
male to female ratio was approximately 2:1, similar to the ratio
reported in white patients.16,20 The mean age at diagnosis was 44.8
years (range, 10e80 years; median, 40.5 years); for males it was
43.5 years (range,10e80 years; median, 43 years) and for females it
was 47.6 years (range, 20e80 years; median, 37 years). The corre-
lation of age with sex was statistically insigniﬁcant (p ¼ 0.706). The
average duration from symptoms to diagnosis was 4.36 years
(range, 1 monthe20 years; median, 3 years), and there was no
signiﬁcant sex or age-based difference at diagnosis. There were 12
patients (54.5%) with initial presentation before age 40 years,
among whom 11 (50.0%) had an established diagnosis before age
40. Case 15 presented with hypopigmented MF (Figure 1A and B),
and the other 21 patients had typical clinical manifestations with
patches to plaques, tumors or erythroderma.
Clinical features
Nineteen of the 22 patients (86%) presented with patches and
plaques, two (9%) showed tumor growths, and one (4.5%) was
erythrodermic. Ten patients (45.5%) had no itching, nine patients
(40.9%) had itching, and three patients (13.6%) had no record of
itching. MF was considered as the ﬁrst differential diagnosis in 10
(45.5%) and the second differential diagnosis in four cases (18.2%),
respectively. According to the medical records, the differential
diagnoses made by the dermatologists after the ﬁrst visit were MF,
eczema, parapsoriasis, psoriasis, subacute cutaneous lupus ery-
thematosus, drug eruption, and pityriasis rosea, in descending or-
der. Case 9 was the only patient who suffered from lymphomatoid
papulosis type B during a 3-year period prior to the diagnosis of MF.
There was no familial clustering. The family histories did not reveal
other lymphoproliferative disorders or hematologic malignancies.
Stages
Among the 22 MF patients listed in Table 1, there were four cases
with advanced stage disease. The four cases were as follows: Case 7
with erythroderma over >80% of the body surface area/Stage IIIA
(Figure 2A), Case 11 with tumors/Stage IIB (Figure 2B), Case 13 with
tumors/Stage IIB, and Case 22 with plaques and bone marrow
involvement/Stage IIIA. There were seven at Stage IA (31.8%), eight
at Stage IB (36.4%), three at Stage IIA (13.6%), two at Stage IIB (9.1%),
and two at Stage IIIA (9.1%) at diagnosis (Figure 3). Two patients
Table 1 Basic demographic characteristics and clinical ﬁndings of the patients.
No. Sex Age at diagnosis (y) Age at onset (y) Elevated LDH Blood eosinophilia History of eczema Stage Types of treatment Death
1 F 77 62 e e þ IA 2 e
2 M 36 28 e e þ IA 2 e
3 M 38 35 e e e IB 1 e
4 M 59 55 þ e þ IB 1 e
5 M 44 34 e þ þ IB 2 e
6 F 20 16 e e e IB 2 e
7 M 80 78 þ þ þ IIIA 3 þ
8 M 46 45 e e e IB 1 e
9 F 62 56 e e þ IA 1 e
10 F 24 23 e e þ IB 2 e
11 F 37 36 e e þ IIB 2 e
12 M 16 11 e þ e IIA 2 e
13 M 65 62 e þ e IIB 2 þ
14 M 38 36 e þ e IA 2 e
15 M 10 7 e e þ IB 2 e
16 M 22 18 e e e IIA 2 e
17 M 16 6 e þ þ IIA 2 e
18 F 80 79 e þ þ IB 2 e
19 M 60 59 e e e IA 1 e
20 M 80 79 e e e IA 2 e
21 F 33 23 e e e IA 2 e
22 M 43 42 e þ þ IIIA 5 e
F ¼ female; LDH ¼ lactate dehydrogenase; M ¼ male.
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stages IIB or higher, while there was no death in the group of stages
lower than IIB. Patients with stages IIB and above were associated
with disease-speciﬁc death (p ¼ 0.026).Laboratory data
Themean, median, andmaximum eosinophil counts were 209, 205,
and 309 cells/mL, respectively. Blood eosinophilia occurred in 36.3%
of MF patients. There was no signiﬁcant association between blood
eosinophilia and previous diagnosis of eczema (p ¼ 0.572). Blood
eosinophilia alone was associated with Stage II disease or higher
(p ¼ 0.029), a more advanced disease presentation. Blood eosino-
philia was also associated with increased number of treatmentFigure 1 Case 15: Hypopigmented mycosis fungoides. The patient presented with widesptypes (p ¼ 0.018). Elevated LDH level was associated with neither a
more advanced disease presentation (p ¼ 0.571), nor an increased
number of treatment types (p ¼ 0.939).Histopathology
The mean number of incisional skin biopsies required to establish a
diagnosis of MF was 1.23 (range, 1e3; median, 1.0). The positive per-
centages of the histopathologic ﬁndings among the 22 MF patients
were as follows. There were 22 patients with dermal lymphocytic
inﬁltrate (100.0%), 21withepidermotropism (95.5%), 21withatypical
lymphocytes (95.5%), 13 (59.1%) with vacuolar interface changes, 12
with Pautrier's microabscesses (54.5%), seven with ﬁbrosis of papil-
lary dermis (31.8%), two with eosinophils (9.1%), two with follicularread hypopigmented, scaly patches and plaques on: (A) the back and (B) the left leg.
Figure 2 Clinical features of two patients with advanced stage disease: (A) Case 7: erythroderma over >80% of the body surface area and (B) Case 11: tumors on the right medial
thigh.
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with plasma cells (0.0%) or histiocytes (0.0%) in the dermal inﬁltrate
(Table 2). None of the above histopathologic features was associated
with advanced disease presentation at Stage II or higher, increased
number of treatment types, or disease-speciﬁc death.Table 2 Comparison of the histopathologic features of patients in the present study
with those in previously reported case series of mycosis fungoides in theTreatment
The average mean number of treatment types was 2.14 (range, 1e5;
median, 2.0). The maximum number of treatment types was ﬁve,
including topical corticosteroids, NB-UVB, retinoids, interferon-a,
and pegylated liposomal doxorubicin in Case 22, as shown in
Table 1. A complete remission was achieved in this case and
maintained for >10 years. The minimum number of treatment
types was one, which is phototherapy. NB-UVB with or without
topical corticosteroids was the main therapy in 17 patients (77.2%).
None of the patients received long-term PUVA treatment because it
is a time-consuming regimen. Three patients were given inter-
feron-a and two patients were given chemotherapy by oncologists.
All patients, except two mortality cases, responded to treatment
with partial or complete remission and no disease progression.
Disease progression was deﬁned as progression into a more
advanced clinical stage or disease-speciﬁc death.Figure 3 Stages of mycosis fungoides in the patients of the present study.Disease outcome and mortality
In the present study, the overall 5-year survival rate was 90.9%. The
5-year survival rate for patients at Stages I and IIA was 100%. The
two patients (9.1%) whose deaths were attributable to MF, Case 7
and Case 13, presented with more advanced disease. Case 7, with
chronic obstructive pulmonary disease and diabetes mellitus under
oral hypoglycemic agents, presented with erythroderma. Histopa-
thology from a specimen of repeat skin biopsy demonstrated
superﬁcial perivascular mixed-cell inﬁltration composed of lym-
phocytes, eosinophils, and neutrophils in the dermis. Some of the
small to medium-sized lymphocytes showed hyperchromatic and
even cerebriform nuclei with exocytosis in the epidermis and
increased mitotic counts. Immunohistochemical studies showed
positive CD4, negative CD8, and diminished expression of CD7. The
clinicopathologic features were compatible with MF at Stage IIIA
without Sezary cells in peripheral blood. The patient received three
types of treatment including topical corticosteroids, NB-UVB, and
PUVA, but he failed to achieve remission. He decided not to seek
other treatment modalities because of his age. The patient died 6
months after the diagnosis had been established. The survival time
from onset of symptoms was 2.5 years. Case 13 with Stage IIB, wholiterature.









N ¼ 22 N ¼ 18 N ¼ 40 N ¼ 103
Dermal lymphocytic inﬁltrate 100.0 100.0 NA 100.0
Epidermotropism 95.5 96.8 51.6 97.1
Atypical lymphocytes 95.5 43.8 91.9 75.5
Vacuolar changes 59.1 28.1 48.4 NA
Pautrier's microabscesses 54.5 43.8 37.1 53.9
Fibrosis of papillary dermis 31.8 71.9 16.1 NA
Eosinophils 9.1 6.3 NA 34.3
Follicular mucinosis 9.1 NA 1.6 17.1
Increased mitotic ﬁgures 4.5 NA NA 16.7
Plasma cells 0.0 3.1 NA 31.4
Histiocytes 0.0 3.1 NA 10.8
N ¼ number of cases; NA ¼ not available.
Table 3 Comparison of the clinical features of the patients in present study with previously reported case series of mycosis fungoides in the literature.
Clinical features Present study Hsiao and
Lee21 2001














Japanese Japanese Whites Blacks
Sex
Male 15 9 27 87 66 60 128 32
Female 7 9 13 44 34 45 85 77
Male to female ratio 2.14 1 2.1 1.98 1.97 1.33 1.51 0.42
Mean age at diagnosis (y) 44.8 46.1 56.4 36.3 60 (median) 63 (median) 54.8 45.3
Average years from symptoms to diagnosis 4.36 6.2 8.0 3.12 2 (median) 1.5 (median) 6.57 6.35
Percent with blood eosinophilia 36.3 NA NA NA NA NA 26.2 35.3
Average maximum eosinophil count (cells/mL) 309 NA NA NA NA NA 328 819
NA ¼ not available.
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Both patients were male and had an established diagnosis at age
65 years. There was no signiﬁcant sex difference in overall sur-
vival (p ¼ 0.334). Age 65 years was signiﬁcantly associated with
disease-speciﬁc death (p ¼ 0.004).
Discussion
In this study, we observed certain demographic, laboratory, and
histopathologic characteristics in the diagnosis of MF in Taiwan.
Comparisons with different races, whites, blacks, and Asians in
regions other than Taiwan, including Japan, Singapore, and Hong
Kong, weremade.We assessed the relationship between laboratory
features and prognosis in patients with MF. The main ﬁnding of the
study was that blood eosinophilia was associated with a more
advanced disease and an increased number of treatment types.
We compared the characteristics of our MF patients with several
previous reported case series focused on different races (Table 3).
Our data showed the classic 2:1 male to female ratio was consistent
with the ratio reported in whites,2,16 but was different from the 1:1
ratio in another case series focused onTaiwanese, reported by Hsiao
and Lee.21 A 2:1 male to female ratio was reported in Hong Kong17
and Singapore,18 where Chinese made up the majority of the pop-
ulation. In several Japanese studies, the mean or median age at
diagnosis of MF was 60 years old.6,19,22 We noted an approxi-
mately 15-year difference in age at diagnosis between Taiwanese
and Japanese patients. Both the study by Hsiao and Lee21 and our
study revealed that theMF population in Taiwanwas about 10 years
younger than that in the West, mainly the United States.2,16 In
contrast, the mean age at diagnosis in Taiwanese was similar to that
in African Americans.16 A difference in the mean age at diagnosis,
59.2 years in whites, 51.5 years in African Americans, versus 51.3
years in Asian/Paciﬁc Islanders, has also been noted in the litera-
ture.13 In the present study, 50% of patients were aged <40 years at
diagnosis. Seven patients (31.8%) experienced onset of symptoms in
the age range 20e40 years, while one patient did not have an
established diagnosis until the mid-forties. Five patients (22.7%)
presented with initial cutaneous manifestations before the age of
20 years. Among these pediatric patients, three (13.6%) had a def-
inite diagnosis of MF established before age 20 years. In general, MF
predominantly affects older adults. Those diagnosed before 20
years of age were reported to account for only 0.5e5% of all MF
patients.17,23 However, in a Singapore study, more than 25% of pa-
tients were <20 years old and less than one-third were >50 years
old.18 It is possible that the incidence of MF in pediatric patients and
young adults has been underestimated. Therefore, clinicians should
be more alert to the possibility of MF in these age groups.
Up to 86% of patients presented with patches and plaques in the
present study. There is a global consensus that most patients have
initial manifestations of limited or generalized patches and/orplaque disease.2,6,16e19,21,24 Despite the difﬁculty of diagnosing MF,
it was considered as the ﬁrst or second differential diagnosis during
the ﬁrst visit in 63.7% of cases in our study. Dermatologists in a
tertiary referral center might be more aware of the symptoms and
signs of MF; however, interpersonal and intrapersonal variations
require further study. MF is most frequently misdiagnosed as
eczema, as it was in a study conducted in Hong Kong.17 Because
pruritus was not found in 45.5% of our MF patients, it could be a key
to differentiating eczema from MF. With 40.9% patients reporting
itchiness, clinicopathologic correlation remains the gold standard
diagnosis of MF. In this study, one of the three pediatric patients
presented with the hypopigmented variant. The association be-
tween hypopigmented MF and young age has been reported.18,23
Hypopigmented MF was also associated with a more indolent
clinical course and better prognosis.4,18,24 Among our patients,
18.2% had advanced stage disease, IIB or higher. In contrast, none
had Stage IIB disease or higher in the previous Taiwanese study.21
Other studies on MF in Asian patients revealed that Stage IIB dis-
ease or higher accounted for 7.0% of patients in Singapore,18 17.5% in
Hong Kong,17 and 16.2%19 and 22.0%,6 respectively, in two reports in
Japan. In theWest, those with Stage IIB disease or higher accounted
for 29.4% of patients with MF reported in the United Kingdom,4 and
28.5%24 and 33.7%,2 respectively, in two reports in the United States.
It is worth noting that the proportion of patients with advanced
clinical stage seems to be higher in Western populations than in
Asian populations. Further study will be needed to determine
whether advanced disease is less common in Asian patients. Two
patients with Stages IIB or higher were associated with disease-
speciﬁc death in this study. It is not unexpected that patients
staged as IIB to IV at diagnosis were more likely to have disease
progression or die of MF than patients with an early stage at
diagnosis.24 Several studies demonstrated that more advanced skin
involvement, the T stage of TNMB classiﬁcation, was associated
with MF-speciﬁc death.2,6,24 Because of the limited number of
cases, our study did not reﬂect the correlation between each TNMB
stage and survival.
Over one-third of our patients were found to have blood
eosinophilia. However, there was no signiﬁcant association be-
tween blood eosinophilia and previous diagnosis of eczema in our
study, which was in contrast to the ﬁndings of Zampella and
Hinds.16 Tancrede-Bohin et al7 suggested blood eosinophilia at
baseline as a prognostic factor of poor outcome in patients with
CTCL. Zampella and Hinds16 observed that MF patients with at least
one instance of eosinophilia presented with later-stage disease and
had poorer responses to treatment. Our study adopted one instance
of eosinophilia as one of the inclusion criteria for patients with
blood eosinophilia. In the present study, blood eosinophilia alone
was associated with more advanced disease presentation and an
increased number of treatment types, while elevated LDH level was
not. The proportion of patients with blood eosinophilia in our
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disparity existed in average maximum eosinophil count (Table 3).
Although blood eosinophilia may partly account for the worse
outcomes observed in African Americans16 and some cases in our
data set, the differences observed in average maximum eosinophil
count and prognosis among races need further investigation.
Increased total serum immunoglobulin E (IgE) levels were
demonstrated to be a signiﬁcant factor for disease progression and
overall survival in one study of early MF,9 but were not reported to
be of signiﬁcance in another study.25 Total IgE level was not
routinely checked in our cases. Additional studies are needed to
clarify the relationship between IgE levels and prognosis.
We compared the histopathologic characteristics of our MF pa-
tients with several previously reported case series (Table 2). Similar
to the results of our study, the data in studies by Hsiao and Lee21 and
Vonderheid et al9 revealed dermal lymphocytic inﬁltrate as an
invariable feature. Atypical lymphocytes, epidermotropism, Pau-
trier'smicroabscesses, andﬁbrosis of papillary dermiswere common
histopathologic ﬁndings without deﬁnite orders of occurrence fre-
quency.9,17,21 None of the above histopathologic features was asso-
ciated with advanced disease presentation, increased number of
treatment types, and disease-speciﬁc death in the present study. In a
study focused on earlyMFat Stage I to IIA, signiﬁcant histopathologic
factors that correlated with both disease progression and overall
survival included the presence of large Pautrier's microabscesses
with 10 atypical lymphocytes, and atypical lymphocytes with
hyperchromatic or vesicular nuclei in the dermal inﬁltrate.9 Early
diagnosis of MF is one of the most challenging problems in derma-
topathology because of the close resemblance to other inﬂammatory
dermatoses. Histopathologic examination alone in the diagnosis of
early MF had low sensitivity and low speciﬁcity.26 Evaluation of
clonal T-cell receptor g gene rearrangement by polymerase chain
reaction could be helpful inmaking a diagnosis in early, lymphocyte-
poor cases of MF.27 Therefore, taking clinical and histopathologic
features with molecular correlation into consideration would make
the diagnosis and prognostic factors of MF more reliable.
Treatmentmodalities in this study include topical corticosteroids,
NB-UVB, PUVA, retinoids, interferon-a, and pegylated liposomal
doxorubicin. The choice of treatment modality for MF primarily
depended on the clinical staging and seemed to be inﬂuenced by the
areas of expertise of clinicians. Patients with early-stage disease
treated by dermatologists usually received skin-directed therapies,
mainly phototherapy with or without topical corticosteroids, while
those treated by oncologists tended to receive systemic therapies
such as interferon-a. All of these patients at Stages I and IIA
responded to treatment without disease progression. In the present
study, the overall 5-year survival rates and 5-year survival rates of
patients at Stage Iwere 90.9% and 100%, respectively, similar to those
reported in the literature, around 90% and nearly 100%, respec-
tively.2,6,14,17 Two of our patients died of MF-speciﬁc disease. The
common characteristics shared by the two patients included male
sex, old age at diagnosis, advanced clinical stage, and blood eosino-
philia. Sex differences in overall survival remain controversial.2,4,5
Age and disease stage are important prognostic factors.4e6 Eosino-
phil counts may be a clue to distinct cytokine proﬁle portending a
worse prognosis.16 As mentioned previously, blood eosinophilia is
associated with more advanced disease and poorer responses to
treatment.
Limitations of our study include its retrospective nature, referral
bias, and a small sample size. The incidence rate of CTCL among
Asians is lower than amongblacks andnon-Hispanicwhites.13,14 The
main limitation of this study is the small number of cases due to the
rarity of MF in Taiwan. A large retrospective study based on multi-
center analysis or the Taiwan National Health Insurance Research
Database is needed for further survey in the Taiwanese population.In conclusion, we have provided local demographic, clinico-
pathologic, and laboratory features in a series of 22 Taiwanese
patients with MF. Blood eosinophilia may be a predictive factor for
advanced clinical stages and increased number of treatment types
in Taiwan. The relationship among blood eosinophilia, prognosis,
and racial differences warrants further study.References
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